Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/PER-088-11
PER-088-11Unknown未知

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLED-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY2127399 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) WHO HAD AN INADEQUATE RESPONSE TO ONE OR MORE TNF-α INHIBITORS

ELI LILLY AND COMPANY,0 sites0 target enrollmentStarted: January 5, 2012Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 85 (—)

Inclusion Criteria

  • •1. AMBULATORY MALES OR FEMALES ≥ 18 YEARS OF AGE.
  • •2. DIAGNOSIS OF ADULT-ONSET RA (OF AT LEAST 6 MONTHSDURATION BUT NOT LONGER THAN 15 YEARS PRIOR TO SCREENING) AS DEFINED BY THE ARA 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RA (APPENDIX 4).
  • •3. HAVE ACTIVE RA DEFINED AS THE PRESENCE OF AT LEAST 8/68 TENEDER AND AT LEAST 8/66 SWOLLEN JOINTS, AS DETERMINED BY THE TENDER JOINT COUNT AND SWOLLEN JOINT COUNTASESSMENT FORMS. (APPENDIX 5).
  • •4. HAVE A SCREENING GREATER THAN 1.2 TIMES THE UPPER LIMIT OF NORMAL (ULN) OR A SCREENING ERYTHROCYTE SEDIMENTATION RATE (ESR) GREATER THAN 28 mm/hr. THESE TESTS MAY BE REPEATED ONE TIME DURING THE SCREENING PERIOD AT THE DISCRETION OF THE INVESTIGATOR.
  • •5. DOCUMENTED HISTORY OF, OR CURRENT, POSITIVE RF AND/OR ANTI-CCP AB TEST.
  • •6. PATIENTS MUST HAVE BEEN TREATED AT APPROVED DOSES WITH AT LEAST ONE BIOLOGIC TNF-α INHIBITOR THERAPY (INFLIXIMAB, CERTOLIZUMAB, GOLIMUMAB, ETANERCEPT, ADALIMUMAB) AND IN THE OPINION OF THE INVESTIGATOR EITHER:
  • •A. STOPPED DUE TO INSUFFICIENT EFFICACY, OR LOSS OF EFFICACY, AFTER AT LEAST 90 DAYS OF TREATMENT,
  • •B. STOPPED DUE TO INTOLERANCE OF SUCH TREATMENT, REGARDLESS OF TREATMENT DURATION.

Exclusion Criteria

  • •1. USE OF AN UNSTABLE DOSE (ie., REQUIRING DOSE ADJUSTMENT) OF NSAIDs (INCLUDING CYCLOOXYGENASE-2 [COX-2] INHIBITORS) WITHIN 6 WEEKS PRIOR TO BASELINE (VISIT 2).
  • •2. USE OF ORAL CORTICOSTEROIDS AT AVERAGE DAILY DOSE OF > 10 mg/day OF PREDNISONE OR ITS EQUIVALENT WITHIN 6 WEEKS PRIOR TO THE BASELINE (VISIT 2).
  • •3. HAVE RECEIVED ANY PARENTERAL (INCLUDING INTRAARTICULAR) CORTICOSTEROID INJECTION WITHIN 6 WEEKS OF BASELINE (VISIT 2).
  • •4. CONCURRENT OR RECENT USE OF ANY BIOLOGIC DMARD (TNF-α INHIBITOR OR NOT). PATIENTS MUST HAVE STOPPED TNF-α INHIBITORS OR ANAKINRA > 28 DAYS; TOCILIZUMAB > 56 DAYS; ABATACEPT > 90 DAYS; RITUXIMAB OR ANY OTHER B CELL BIOTHERAPY > 1 YEAR, OR ANY OTHER BIOLOGICAL DMARD > 5 HALF- LIVES PRIOR TO BASELINE.
  • •5. HAVE RECEIVED AN ORAL CALCINEURIN INHIBITOR (eg., CYCLOSPORIN OR TACROLIMUS) AT ANYTIME WITHIN 8 WEEKS OF BASELINE (VISIT 2) OR ANY PREVIOUS TREATMENT WITH ALKYLATING AGENTS SUCH AS CYCLOPHOSPHAMIDE OR CHLORAMBUCIL.
  • •6. HAVE SUFFERED A SEVERE REACTION TO ANY BIOLOGICAL TREATMENT THAT, IN OPINION OF THE RESEARCHER, WILL MEANS AN UNACCEPTABLE RISK FOR THE PATIENT IF WILL BE PARTICIPATING IN THE STUDY.

Investigators

Sponsor
ELI LILLY AND COMPANY,

Similar Trials

Active, not recruiting
Phase 1
A study to evaluate the efficacy and safety ofbimekizumab in subjects with activenonradiographic axial spondyloarthritisonradiographic axial spondyloarthritisMedDRA version: 20.0Level: LLTClassification code 10076297Term: Non-radiographic axial spondyloarthritisSystem Organ Class: 100000004859
EUCTR2017-003064-13-BGCB Biopharma SR240
Active, not recruiting
Phase 1
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)TRANSFUSION-DEPENDENT ANEMIA DUE TO IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITHOUT DELETION 5Q [31] AND UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTMedDRA version: 19.0Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864
EUCTR2009-011513-24-BECelgene Corporation228
Recruiting
Not Applicable
SAFETY AND IMMUNOGENICITY OF V114 IN ADULTS INFECTED WITH HIV-J13 Pneumonia due to Streptococcus pneumoniaePneumonia due to Streptococcus pneumoniaeJ13
PER-021-18Merck Sharp & Dohme Corp., una subsidiaria de Mer·ck & Co. Inc.,
Active, not recruiting
Phase 1
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PROGRESS)
EUCTR2018-004337-32-GBAllergan Limited750
Active, not recruiting
Phase 1
A MAINTENANCE STUDY OF THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN ULCERATIVE COLITISModerately to Severely Active Ulcerative ColitisMedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856
EUCTR2017-003238-96-GBEli Lilly and Company1,044